



New Natural Products as Candidates for the Discovery of Anti-MRSA Drugs

Guest Editors:

Prof. Dr. Maya Zaharieva

Department of Infectious Microbiology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria

Prof. Dr. Hristo Najdenski

Department of Infectious Microbiology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Acad. G. Bonchev Str., 1113 Sofia, Bulgaria

Deadline for manuscript submissions:

closed (31 January 2024)

Message from the Guest Editors

Dear Colleagues,

The prevention of the methicillin-resistant *Staphylococcus aureus* (MRSA) that is spreading in healthcare facilities is a huge infection control challenge because these infections remain a serious cause of healthcare-associated infections around the world. Increased public awareness towards MRSA in the framework of various initiatives, events, etc., may contribute to the search for new products of natural origin (plant, animal, microalgal, etc.) as candidates for anti-MRSA control and therapy. These include various essential oils, small antimicrobial peptides of animal origin, bacteriocines, and different plant compounds. Attention has been focused on a number of nanocarriers, such as liposomes, microemulsion systems for drug delivery, nanocapsules, solid lipid nanoparticles, etc.

In this context, this Special Issue will focus on recent studies on the modern ways and future directions to search for the next generation safe and effective antimicrobial compounds, including those derived from phytochemicals, antimicrobial peptides, metalloantibiotics, efflux pump inhibitors, etc., to control the infections caused by emerging MDR pathogens.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi